Today: 9 June 2026
DCC share price slips in early London trade as short sellers circle — what to watch next
2 March 2026
1 min read

DCC share price slips in early London trade as short sellers circle — what to watch next

London, March 2, 2026, 08:12 GMT — Regular session.

  • DCC slipped 0.7% in the morning session, having wrapped up last week at 5,185 pence.
  • Short interest in the stock now stands at roughly 5.6% of shares, according to a weekend report.
  • March conference talks and the May 19 full-year results are the next markers investors are eyeing for new cues.

Monday morning in London saw DCC slipping 0.7% to 5,150 pence by 0812 GMT, following a previous close of 5,185 pence. The stock moved within a 5,120 to 5,200 pence range not long after the open.

Selling picked up as traders zeroed in on a spike in flagged short positions—this, after a weekend report highlighted a notable jump in hedge fund wagers against the Irish distributor. More shorts in the mix? That usually stirs up more daily swings, particularly when fresh headlines hit and portfolios get shuffled fast.

Short interest in DCC has shot up to about 5.6% of shares outstanding—roughly £250 million—according to market filings cited by The Times. Israel “Izzy” Englander’s Millennium holds the biggest disclosed short, close to 3%, valued north of £130 million. Other disclosed shorts came from Marshall Wace, Qube Research & Technologies, and Two Sigma. Short sellers are betting the stock price will drop by selling borrowed shares and hoping to buy them back cheaper. The Times

Awkward timing for both camps. DCC shares, the report pointed out, have climbed from a little above £40 back in January to finish at £51.85 on Friday—so shorts have been stacking up even as the stock advanced.

DCC, which sits on the FTSE 100, runs sales, marketing, and support services, with a focus on energy and technology.

Hard catalysts line up on the calendar: DCC is booked for the Berenberg UK Corporate Conference in London on March 19, then heads to Jefferies Pan-Euro Mid-Cap Conference March 24. After that, final results for the year ending March 31, 2026 land on May 19, per the investor calendar.

DCC’s most recent analyst consensus—last seen Jan. 30—puts adjusted operating profit at £622 million for continuing operations, with adjusted EPS expected at 425 pence for the upcoming May report.

Short-position data remains in focus—any uptick or pullback there could jolt sentiment fast, even in the absence of fresh company headlines.

The numbers that get disclosed don’t tell the whole story. Only short positions above certain thresholds appear in public filings, and funds have ways to hedge or shift their exposure before anything shows up—leaving outsiders to piece together conviction from incomplete signals.

The stock now faces a key question: will Monday’s initial drop tempt more sellers, or could buyers re-emerge before DCC’s March conference slots and the full-year numbers set for May 19?

Stock Market Today

  • GSK to Acquire Nuvalent for $10.6 Billion to Boost Oncology Pipeline
    June 9, 2026, 9:41 AM EDT. GSK announced a $10.6 billion cash acquisition of U.S.-based Nuvalent, offering $124 per share, a 40% premium. The purchase aims to strengthen GSK's oncology portfolio ahead of patent expiries on key HIV treatments. Nuvalent awaits FDA decisions on two lung cancer drugs, zidesamtinib and neladalkib, with potential 2027 market entry. The deal also includes earlier-stage cancer treatments, including NVL-330. Nuvalent shares rose nearly 39% premarket, while GSK shares slipped 1.4%. GSK plans to finance the deal through debt and cash, expecting sales and profit boosts from 2027 and 2029, respectively, without impacting its credit rating. The acquisition intensifies GSK's lung cancer market presence, competing with firms like AstraZeneca, Roche, and Pfizer.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
WiseTech Global stock slides 4.7%: AI job cuts, CEO buy and dividend dates now in focus
Previous Story

WiseTech Global stock slides 4.7%: AI job cuts, CEO buy and dividend dates now in focus

Vodafone stock price dips after Amazon Leo satellite deal; VOD.L investors eye May results
Next Story

Vodafone stock price dips after Amazon Leo satellite deal; VOD.L investors eye May results

Go toTop